---
title: "BlackRock Tech and Private Equity Term Trust | 10-Q: FY2025 Q2 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/252917024.md"
datetime: "2025-08-13T20:32:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/252917024.md)
  - [en](https://longbridge.com/en/news/252917024.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/252917024.md)
generator: "portal-rs"
---

# BlackRock Tech and Private Equity Term Trust | 10-Q: FY2025 Q2 Revenue: USD 0

Revenue: As of FY2025 Q2, the actual value is USD 0.

EPS: As of FY2025 Q2, the actual value is USD -0.61.

### Segment Revenue

-   Revenue was $0 for the three and six months ended June 30, 2025, compared to $47,000 and $94,000 for the same periods in 2024.

### Operational Metrics

-   Net loss was $3.1 million for the three months ended June 30, 2025, compared to $5.5 million for the same period in 2024. For the six months ended June 30, 2025, net loss was $11.3 million compared to $12.2 million for the same period in 2024.
-   Gross loss was $0 for the three and six months ended June 30, 2025, compared to $48,000 and $62,000 for the same periods in 2024.
-   Operating expenses were $2.5 million for the three months ended June 30, 2025, compared to $4.9 million for the same period in 2024. For the six months ended June 30, 2025, operating expenses were $5.2 million compared to $10.7 million for the same period in 2024.
-   Research and development expenses were $1.1 million for the three months ended June 30, 2025, compared to $987,000 for the same period in 2024. For the six months ended June 30, 2025, research and development expenses were $2.4 million, the same as the previous year.
-   General and administrative expenses were $1.4 million for the three months ended June 30, 2025, compared to $3.9 million for the same period in 2024. For the six months ended June 30, 2025, general and administrative expenses were $2.8 million compared to $8.2 million for the same period in 2024.

### Cash Flow

-   Operating cash flow: Net cash used in operating activities was $4.6 million for the six months ended June 30, 2025, compared to $6.0 million for the same period in 2024.
-   Investing cash flow: No cash used in investing activities for the six months ended June 30, 2025, compared to $346,000 used in the same period in 2024.
-   Financing cash flow: Net cash provided by financing activities was $7.2 million for the six months ended June 30, 2025, compared to $1.4 million for the same period in 2024.

### Unique Metrics

-   Forward sales contract expense was $512,000 for the three months ended June 30, 2025, and $5.8 million for the six months ended June 30, 2025.
-   Change in fair value of warrant liabilities was $0 for the three and six months ended June 30, 2025, compared to $136,000 and $66,000 for the same periods in 2024.
-   Interest expense was $0 for the three months ended June 30, 2025, compared to $797,000 for the same period in 2024. For the six months ended June 30, 2025, interest expense was $5,000 compared to $1.6 million for the same period in 2024.
-   Other expense was $123,000 for the three months ended June 30, 2025, compared to $0 for the same period in 2024. For the six months ended June 30, 2025, other expense was $258,000 compared to $0 for the same period in 2024.

### Future Outlook and Strategy

-   Core Business Focus: The company plans to complete the Investigational New Drug (IND) enabling studies and IND submission by 2026 and subsequently enter a Phase I investigator-sponsored clinical trial in the second half of 2026.
-   Non-Core Business: The company is actively seeking strategic partnerships to co-develop or out-license therapeutic assets and engage with potential collaborators to expand developmental opportunities.
-   Priority: Emphasis on developing scalable, affordable, off-the-shelf cell therapies for cancer and autoimmune diseases, with a focus on ERNA-101 and ERNA-201 product candidates.

### Related Stocks

- [BTX.US](https://longbridge.com/en/quote/BTX.US.md)

## Related News & Research

- [Inside Coca-Cola’s secretive innovation labs: How the beverage giant wants to automate dirty soda and refreshers](https://longbridge.com/en/news/296681725.md)
- [Bank of America Corp DE Acquires 173,486 Shares of Trustmark Corporation $TRMK](https://longbridge.com/en/news/296675221.md)
- [Bank of America Corp DE Boosts Stake in Magnite, Inc. $MGNI](https://longbridge.com/en/news/296675219.md)
- [Bank of America Corp DE Boosts Holdings in nLight $LASR](https://longbridge.com/en/news/296675210.md)
- [Bank of America Corp DE Raises Holdings in McGrath RentCorp $MGRC](https://longbridge.com/en/news/296675165.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**